Endocyte

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.

Endocyte headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $9.6B in funding across 84 round(s). With a team of 51-100 employees, Endocyte is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Endocyte, raised $26.0M. Discover more about their projects, partnerships, and impact on our platform.